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anti–tumor necrosis factor treatment. If previous Mtb exposure
is diagnosed, chemoprophylaxis may be indicated to prevent active TB.
Regarding the research implications, the host–pathogen
interaction is finely balanced, with only a small subset of Mtb-
exposed individuals developing pulmonary disease to continue
transmission (1, 4). The clinical observations that are emerging from
the biologic treatment era provide entirely novel and highly relevant
insights into human immune function and host–pathogen
interactions. The increase in active TB after immune checkpoint
inhibition suggests that excessive immunity may be just has harmful
as insufficient immunity. Supporting this concept, Comstock and
colleagues demonstrated in a study of 82,000 individuals that a
strong response to TB antigens, which should be considered
protective, actually associates with progression to active TB (8).
Infection of mice deficient in PD-1 results in rapidly lethal
inflammation (9, 10), consistent with a protective role in TB. Perhaps
the most sobering implication is that it reinforces the finely balanced
knife edge of the human–Mtb interaction. Simply driving an
exaggerated immune response, without first defining determinants of
progression versus protection in TB, risks inadvertently accelerating
transmission and worsening the pandemic in the longer term (4). n
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Mucin Concentrations and Peripheral Airway
Obstruction in Chronic Obstructive Pulmonary Disease
To the Editor:
Recent studies have revealed that increased airway mucin
concentrations in chronic obstructive pulmonary disease (COPD) slow
mucociliary clearance and produce mucus adhesion with mucus plug
formation (1). Furthermore, data from SPIROMICS (Subpopulations
and Intermediate Outcomes in COPD Study) demonstrated an
association between induced sputum (IS) mucin concentrations and
measures of airflow obstruction, e.g., FEV1 and FEV1/FVC (2).
Peripheral airways are the earliest and dominant sites of airflow
obstruction in COPD, and Hogg and colleagues demonstrated that
intraluminal mucus plugs contribute a major component to peripheral
airway obstruction (3). For development of targeted therapies, it is
important to understand whether there are associations between mucus
concentrations and peripheral airway obstruction in COPD.
We hypothesized that sputum mucin concentrations would
reflect small airway mucus concentrations and hence the likelihood
of small airway mucus plaques/plug-mediated obstruction. This
hypothesis was based on mucus transport measurements reporting
peripheral-to-central mucus transport (4) and on analyses of sputum
that identified mucus plugs, which, based on their small size, may be
of peripheral airway origin. Accordingly, we tested for associations
between sputum mucin concentrations and characteristics with
complementary spirometric and computed tomography (CT)
measures of peripheral airway obstruction in the SPIROMICS cohort.
Methods
A complete description of the demographics of the SPIROMICS
cohorts and methods can be found in previous publications (2, 5). For
studies of mucus/peripheral airway associations, 884 subjects from
whom IS was collected through SPIROMICS were analyzed. For IS
analyses, total mucin concentrations were measured by gel-filtration
chromatography/refractometry (6). Technicians who were blinded to
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the spirometric/CT outcomes scored sputum samples based on plug
density and watery versus mucoid properties. These technicians were
also blinded as to airway structure and function measurements.
Forced expiratory flow, midexpiratory phase (FEF25–75%) spirometry
measurements and CT measures of peripheral airway obstruction,
including measures of residual volume/total lung volume (RV/TLV)
and parametric response mapping–functional small airway disease
(PRM-FSAD), were obtained according to SPIROMICS protocols (5, 7).
Associations were studied with ANOVA and Tukey-Kramer tests using
the mucin concentration variable divided into quartiles (2). In addition,
airway dimensions, stratified by airway anatomic level (8), were related
to IS total mucin concentrations and mucoid characteristics.
Results
Analyses of mucin and peripheral airway spirometric parameters
revealed that FEF25–75% was inversely related to total mucin
concentrations and mucus plug density (Figures 1A and 1B).
Analyses of correlation between mucus properties and CT
measures of peripheral airway function revealed that both
increased total mucin values and mucoid sputum were also
associated with increased RV/TLV (Figures 1C and 1D) and PRM-
FSAD (Figures 1E and 1F) values.
Significant associations between total sputum mucin
concentrations and airway wall dimensions were also observed
(Table 1). Higher mucin concentrations were associated with
greater relative airway wall thickness, as defined by the percent
wall area relative to the total airway area. This association
was evident at the more peripheral subsegmental and sub-
subsegmental levels, but not in the more centrally located airways.
Partitioning the measure of percent wall area into absolute wall and
lumen areas revealed that higher mucin concentrations were associated
with thinner walls and even narrower lumens, resulting in a higher
mucin–greater percent wall area association. A 1-SD-unit higher mucin
concentration was associated with a 0.34-mm2-smaller subsegmental
airway lumenal area (3.6% narrower). Similar associations with
subsegmental and sub-subsegmental airway dimensions were observed
for mucoid versus watery mucus consistency (not shown).
Discussion
SPIROMICS sputum total mucin concentrations, mucus consistency,
and plug density were associated with spirometric and CT measures
of peripheral airway disease. A strong association was noted in the
relationship between mucin concentration and a spirometrically
determined measure of peripheral airflow, i.e., FEF25–75%. Associations
with total mucin concentrations and consistency were also observed
with CT measures of RV/TLV and PRM-FSAD.
Of particular relevance to the relationships between airway
mucins and regional airway obstruction, analyses of mucin
concentrations and airway wall dimensions revealed that the
relationships were strongest in the more peripheral CT-resolved
airways. Although we speculate that mucus hyperconcentration


























































































P<0.01 P=0.03 P=0.017 P=0.038
P<0.001 P=0.03 P<0.01
Figure 1. Relationships between total mucin concentrations and mucus properties and peripheral airway spirometric and computed tomography indices.
(A) Total mucin concentration versus FEF25–75% (POST FEF2575%). (B) Mucus plug density versus FEF25–75%. (C) Total mucin concentration versus
residual volume/total lung volume (RV/TLV). (D) Sputum mucus consistency versus RV/TLV. (E) Total mucin concentration versus parametric response
mapping–functional small airway disease (PRM-FSAD). (F) Sputum consistency versus PRM-FSAD. The horizontal line in the boxes represents the median,
and the bottom and top of the boxes represent the 25th and 75th percentiles, respectively. The whiskers represent the upper adjacent value (75th percentile
plus 1.5 times the interquartile range) and the lower adjacent value (25th percentile minus 1.5 times the interquartile range), and the dots represent outliers.
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will be required to test the converse notion, i.e., that narrowed
lumens produce mucus hyperconcentration/stasis. Nevertheless,
because reductions in airway area produce squared reductions in
airflow, the 1-SD-unit higher mucin concentration/0.34-mm2-
smaller airway subsegmental airway lumenal airway relationship
suggests that the magnitude of mucus obstruction is
pathophysiologically relevant.
Data from theoretical, in vitro, and animal model studies have
established strong relationships among mucin concentrations,
mucus transport rates, and, in the event of hyperconcentrated
mucus, plaque/plug formation within airway lumens (1). More
recently, measures of mucus adhesive interactions with airway
surfaces as a function of mucus concentration have been reported,
and again revealed strong mucus concentration–airways adhesion
relationships (9). Analyses have been conducted that juxtapose
mucus adhesive forces with the shear forces generated by
peripheral airways (low flow) versus central airways (high airflow).
These studies confirmed the notion that it is difficult to clear mucus
adhered to small airway surfaces by cough as compared with the
relative ease of disadhering and expectorating mucus from central
airways (9). Thus, it appears likely that mucin concentrations in the
ranges measured in these studies, coupled with minimal peripheral
airway cough clearance, will produce mucus accumulation and plug
formation in peripheral COPD airways.
Notably, our measurements of mucin concentrations were
obtained from IS, which likely represents material expectorated
from central airways. Despite mucociliary clearance studies
showing peripheral-to-central mucus transport (4), we cannot
unambiguously assume that the mucins/mucus plugs collected
by sputum induction reflect peripheral airway materials.
Mitigating this concern is the likelihood that the increased mucin
concentrations measured in IS reflects a global airway disease
process that produces mucus hyperconcentration both centrally
and peripherally. However, direct bronchoscopic measurements
of peripheral airway mucus concentrations will be required to
establish the relationship between large and small airway mucus
concentrations.
Quantifying and elucidating the pathogenesis of peripheral
airway disease in COPD is a key requirement for future therapeutics
development and patient care. Sputum mucin concentrations may
prove to be a useful biomarker in smoking subjects at risk for COPD
(2) and, in view of the reported relationship between small airway
mucus obstruction and early death, in COPD subjects with later
disease at risk of premature death (10). n
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b P Value b P Value
Percent wall area
Lobar airways 50.3 (5.4) 0.0 0.790 0.0 0.879
Segments 60.2 (5.2) 0.1 0.576 0.1 0.413
Subsegments 63.8 (4.5) 0.2 0.028 0.2 0.003
Sub-subsegments 65.8 (4.8) 0.2 0.014 0.2 0.002
Wall area, mm2
Lobar airways 69.2 (27.8) 20.4. 0.419 20.3 0.434
Segments 35.1 (11.9) 20.2 0.225 20.2 0.228
Sub-segments 22.3 (8.7) 20.3 0.018 20.3 0.032
Sub-subsegments 17.2 (7.8) 20.3 0.006 20.2 0.053
Lumen area, mm2
Lobar airways 72.4 (43) 20.1 0.900 0.1 0.895
Segments 25.1 (16.3) 20.2 0.391 20.2 0.372
Subsegments 13.5 (8.7) 20.3 0.049 20.3 0.030
Sub-subsegments 9.7 (7.0) 20.3 0.008 20.2 0.009
Definition of abbreviation: CT = computed tomography.
Mean differences in airway dimensions were calculated using generalized
estimating equations with exchangeable covariance matrix and robust
standard errors to account for multiple airway measures per participant
(N = 884) and linear regression to adjust for covariables (age, sex, height,
race/ethnicity, CT dose, CT model, and lung volume achieved at CT).
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Cigarette Smoking Acutely Decreases Serum Levels of
the Chronic Obstructive Pulmonary Disease
Biomarker sRAGE
To the Editor:
Chronic obstructive pulmonary disease (COPD) is caused by a
combination of genetic susceptibility and chronic exposure to
inhaled noxious gases such as cigarette smoke. To monitor
progression and classification of this complex disease, reliable
biomarkers are needed. One of the most promising biomarkers
for COPD, especially reflecting the presence and progression of
emphysema, is sRAGE (soluble receptor for advanced glycation
end-products) (1).
The RAGE receptor is a multiligand pattern recognition
receptor that is mainly expressed by type I alveolar epithelial cells.
RAGE activation induces NF-ĸB–mediated proinflammatory
responses and is involved in alveolar tissue damage (2). RAGE
signaling is inhibited by the endogenous decoy receptor
sRAGE, which binds freely circulating RAGE ligands and
prevents homodimerization of RAGE, which is necessary for
activation. Production of sRAGE takes place by alternative
splicing or proteolytic cleavage. In patients with COPD,
expression of RAGE was found to be increased in lung tissue,
whereas circulating concentrations of sRAGE were decreased
(1, 3). The cause of the lower circulating sRAGE levels in
patients with COPD is currently unknown. Furthermore, little
is known about the effect of smoking on circulating levels of
sRAGE. In the current study, we investigated the effect of
smoking on serum sRAGE levels, which should be taken
into account when investigating sRAGE as a biomarker for COPD.
Serum samples from patients with COPD (Global Initiative
for Chronic Obstructive Lung Disease [GOLD] stage I, n = 25;
GOLD stage II, n = 12; GOLD stage III, n = 20; and GOLD stage
IV, n = 16) (ClinicalTrials.gov Identifier: NCT00850863) were
used. Additionally, serum samples were obtained from light-
social-smoking control subjects without airway obstruction
(young: 18–40 yr, n = 49; old: .40 yr, n = 26) with age- and
smoking history–matched patients with mild COPD (n = 13)
(ClinicalTrials.gov Identifier: NCT00807469) (4). Serum
samples were collected from the young and old healthy control
subjects and matched patients with COPD after they went at least
2 days without smoking, and 2 hours after they smoked three
cigarettes within 1 hour. Exhaled carbon monoxide was analyzed
using a Micro1 Smokerlyzer at baseline to determine whether
the individuals had not smoked recently, and after smoking to
determine whether they had inhaled a sufficient amount
of cigarette smoke. Serum sRAGE levels were measured
using a simplified immunoprecipitation in 96-well ELISA
format–coupled liquid chromatography mass spectrometry assay
(5), a novel and fully validated method to measure sRAGE with
high specificity and selectively, and a commercially available
sRAGE ELISA (Human RAGE DuoSet DY1145; R&D Systems).
All study protocols were approved by the Medical Ethics
Committee of the University Medical Center Groningen,
Groningen, the Netherlands, and all subjects provided written
informed consent. Furthermore, all clinical procedures were
performed according to the standards set by the latest Declaration
of Helsinki.
Patients with COPD of all stages of severity had significantly
lower serum sRAGE levels than control subjects (Figure 1A).
Furthermore, patients with severe COPD (GOLD stage IV)
had lower circulating sRAGE levels than patients with mild
(GOLD stage I) COPD. The serum sRAGE levels were
independent of age, as the levels in young (,40 yr old) control
subjects were similar to those observed in old (.40 yr old)
control subjects. Next, we investigated the acute effect of smoking
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